Robert W. Baird Lowers Vor Biopharma (NYSE:VOR) Price Target to $14.00

Vor Biopharma (NYSE:VOR) had its price objective dropped by investment analysts at Robert W. Baird from $22.00 to $14.00 in a research note issued on Friday,Benzinga reports. The firm currently has an “outperform” rating on the stock.

Several other analysts have also recently issued reports on the stock. Barclays reduced their price target on shares of Vor Biopharma from $10.00 to $3.00 and set an “overweight” rating on the stock in a research report on Wednesday, August 14th. JMP Securities reissued a “market outperform” rating and issued a $12.00 price target on shares of Vor Biopharma in a research report on Friday, September 6th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $17.50 price objective on shares of Vor Biopharma in a research report on Friday, September 6th. Seven research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Vor Biopharma has a consensus rating of “Buy” and an average target price of $11.36.

Vor Biopharma Stock Up 14.9 %

NYSE:VOR opened at $0.96 on Friday. Vor Biopharma has a 52 week low of $0.63 and a 52 week high of $3.14. The stock’s fifty day moving average is $0.80 and its two-hundred day moving average is $1.07. The stock has a market capitalization of $65.53 million, a price-to-earnings ratio of -0.55 and a beta of -0.40.

Vor Biopharma (NYSE:VOR) last posted its earnings results on Thursday, August 8th. The company reported ($0.41) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.41). On average, sell-side analysts expect that Vor Biopharma will post -1.51 EPS for the current fiscal year.

Hedge Funds Weigh In On Vor Biopharma

Institutional investors and hedge funds have recently modified their holdings of the company. Acadian Asset Management LLC purchased a new stake in Vor Biopharma during the first quarter worth approximately $126,000. Vanguard Group Inc. raised its holdings in Vor Biopharma by 4.0% during the first quarter. Vanguard Group Inc. now owns 1,812,899 shares of the company’s stock worth $4,297,000 after purchasing an additional 69,436 shares in the last quarter. Hsbc Holdings PLC lifted its position in shares of Vor Biopharma by 177.0% during the 2nd quarter. Hsbc Holdings PLC now owns 49,038 shares of the company’s stock worth $51,000 after buying an additional 31,333 shares during the last quarter. Cubist Systematic Strategies LLC acquired a new position in shares of Vor Biopharma in the 2nd quarter valued at $53,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Vor Biopharma in the 2nd quarter valued at $63,000. Institutional investors and hedge funds own 97.29% of the company’s stock.

Vor Biopharma Company Profile

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.